Blood Loss, Hypovolemic Shock
Conditions
Keywords
Resuscitative agent, Vasopressor
Brief summary
This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-II efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock. Centhaquine is highly safe and well tolerated. Toxicological studies showed high safety margin in preclinical studies. Its safety and tolerability has been demonstrated in a human phase I study in 25 subjects (CTRI/2014/06/004647; NCT02408731).
Detailed description
Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) has been found to be an effective resuscitative agent in rat, rabbit and swine models of hemorrhagic shock, it decreased blood lactate, increased mean arterial pressure, cardiac output, and decreased mortality. An increase in cardiac output during resuscitation is mainly attributed to an increase in stroke volume. Centhaquine acts on the venous α2B-adrenergic receptors and enhances venous return to the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic receptors to reduce sympathetic activity and systemic vascular resistance. Unlike presently used vasopressors, centhaquine increased mean arterial pressure by increasing stroke volume and cardiac output, and it decreased systemic vascular resistance. The most common adverse effects of vasopressors as a class include arrhythmias, fluid extravasation, and ischemia. Centhaquine does NOT act on beta-adrenergic receptors, and therefore the risk of arrhythmias is mitigated. It is NOT a vasopressor; however, it increases blood pressure and cardiac output by augmenting venous blood return to the heart and enhanced tissue perfusion by arterial dilatation. Enhancing tissue perfusion is a significant advantage over existing vasopressors.
Interventions
DRUGNormal Saline
In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
DRUGCenthaquine
In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
Sponsors
Pharmazz, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adult males or females aged 18-70 years. * Patients with Hypovolemic shock due to blood loss admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment (endotracheal intubation; fluid resuscitation and vasopressors). Standard of care to be provided to the patients shall be the one used in the particular hospital setup. * Body weight 45 kg - 85 kg. * Female subject is either: (1) Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or, (2) If of childbearing potential, agrees to use any of the following effective separate forms of contraception throughout the study, up to and including the follow-up visits: Condoms, sponge, foams, jellies, diaphragm or intrauterine device, or A vasectomised partner OR abstinence.
Exclusion criteria
* Terminal illness * Development of any other terminal illness not associated with Hypovolemic shock due to blood loss during the 28 day observation period * Patient with severe brain injury or with a Glasgow Coma Scale (GCS) \< 8 * Type of injury is not known * Inability to obtain intravenous access * Known pregnancy * Cardiopulmonary resuscitation (CPR) before randomization * Presence of a do not resuscitate order * Patient taking beta adrenergic antagonists * Untreated tension pneumothorax * Untreated cardiac tamponade * Bilateral absent pupillary light reflex (both pupils fixed and dilated) * Patient is participating in another interventional study * Patients with systemic diseases which were already present before having trauma, such as: cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of PMZ-2010 related adverse events | 28 days | The primary objective of the study is to determine incidence of drug (PMZ-2010) related adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Volume of blood products administered | 48 hours | Total volume of blood products administered - Mean through 48 hours |
| Vasopressor(s) infused | 48 hours | Amount of total vasopressor(s) infused - Mean through 48 hours |
| Doses of study drug | 48 hours | Number of doses of study drug administered in first 48 hours post randomization |
| Change in systolic and diastolic blood pressure | 48 hours | Change in systolic and diastolic blood pressure - Mean through 48 hours |
| Change in blood lactate level | 48 hours | Change in blood lactate level - Mean through 48 hours |
| Change in base-deficit | 48 hours | Change in Base-deficit - Mean through 48 hours |
| Change in platelet count | 48 hours | Change in platelet count as part of coagulation parameters mean through 48 hours. Platelets are parts of the blood that helps the blood clot. Average platelet counts are 150,000 to 450,000 number of platelets per microliter. |
| Volume of fluid administered | 48 hours | Total volume of fluid administered - Mean through 48 hours |
| Change in international normalized ratio (INR) | 48 hours | Change in international normalized ratio (INR) as part of coagulation parameters mean through 48 hours. The results of the prothrombin time test vary from laboratory to laboratory, therefore, a ratio called the international normalized ratio (INR) is calculated. It allows for differences in laboratories across the world so that test results become more relevant and can be compared. The average INR range is 0.8 to 1.1. |
| Change in fibrinogen | 48 hours | Change in fibrinogen as part of coagulation parameters mean through 48 hours. Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. The reference range for fibrinogen is 150-400 mg/dL |
| Change in Multiple Organ Dysfunction Syndrome Score | 28 days | Change in Multiple Organ Dysfunction Syndrome Score (MODS) - Mean through 28 days. MODS is a 5 grade scale from 0 to 4, where 0 is the best and 4 is the worst outcome. |
| Change in Acute Respiratory Distress Syndrome | 28 days | Change in Acute Respiratory Distress Syndrome (ARDS) - Mean through 28 days. ARDS will be determined using Murray Score for Acute Lung Injury which is based upon radiological findings, oxygenation status, ventilation status of the patient. A lower score of 0 is the best and about 2.5 is the worst outcome. |
| Change in Glasgow coma score | 28 days | Change in Glasgow coma score (GCS) - Mean through 28 days. GCS is a 15 point scale to assess the level of consciousness of patients where less than 3 is comatose state and 15 is fully awake. |
| Stay in hospital, in ICU and/or on Ventilator | 28 days | Days in hospital, in ICU and/or on Ventilator - Mean through 28 days |
| Incidence of mortality | 28 days | Proportion of patients with all-cause mortality at 48 hours and 28 days |
| Change in prothrombin time | 48 hours | Change in prothrombin time as part of coagulation parameters mean through 48 hours. Prothrombin time (PT) is a blood test that measures the time it takes for the blood to clot. The average time range for blood to clot is about 10 to 14 seconds. |
Countries
India
Outcome results
None listed